Ligand Pharmaceuticals Incorporated — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing, not a standalone fourth-quarter report. Ligand operates as a biopharmaceutical royalty aggregator and technology licensor; revenue primarily comes from royalties, Captisol sales, and contract fees and milestones. OmniAb is reported as discontinued operations following its 2022 spin-off.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Total revenue | $131.3 million | $196.2 million |
| Royalties | $83.9 million | $72.5 million |
| Captisol revenue | $28.4 million | $104.5 million |
| Contract revenue | $19.0 million | $19.2 million |
| Operating income from continuing operations | $11.9 million | $3.0 million |
| Net income (loss) from continuing operations | $53.8 million | $(5.2) million |
| Net income (loss), including discontinued operations | $52.2 million | $(33.4) million |
| Cash provided by operating activities | $49.6 million | $137.9 million |
- Total revenue declined 33%; royalty revenue rose 16%. Captisol revenue fell as COVID-related remdesivir demand receded: COVID Captisol revenue was zero in 2023 versus $88.1 million in 2022. Core Captisol sales increased to $28.4 million from $16.4 million, primarily due to order timing.
- Operating margin was approximately 9.1% (operating income divided by revenue). Net income benefited substantially from investment gains, so reported earnings were not solely driven by operating performance.
- At year-end, cash and cash equivalents were $23.0 million and short-term investments were $147.4 million, totaling approximately $170.3 million. Current assets were $237.4 million versus current liabilities of $16.8 million.
- The $76.9 million remaining principal on the 0.75% convertible notes was repaid at maturity in May 2023. Ligand entered a secured, $75 million revolving facility in October; year-end availability was $74.5 million after a $0.5 million letter of credit. The filing says the company believes available funds, operating cash flow, and financing access are adequate for planned needs.
Material changes and unusual items
- Revenue fell from $196.2 million to $131.3 million, principally reflecting the decline in COVID-related Captisol sales. Royalty growth was led by Kyprolis, Rylaze, and Pneumosil; Teriparatide royalties declined.
- Operating costs and expenses decreased 37% to $121.5 million, including lower Captisol costs and lower R&D and G&A expenses. 2022 expenses included a $9.8 million Captisol capacity-related impairment and higher share-based compensation.
- Other income was $51.7 million, including a $46.4 million gain on short-term investments. This included a $44.4 million realized gain from selling 5.0 million Viking shares; the remaining Viking investment was valued at $32.2 million at year-end. Ligand also recorded a $2.1 million gain on the Pelican sale.
- Ligand sold Pelican to Primrose Bio, retained existing royalty rights, and received an equity interest; it also invested $15 million in Primrose-related economic rights and holds a 49.9% stake in Primrose Bio. The reported equity-method investment was $12.6 million at year-end.
- Ligand acquired Novan assets for a reported net cash outlay of approximately $10.4 million, including berdazimer gel and the NITRICIL platform; ZELSUVMI was FDA-approved in January 2024. It also invested $30 million for a 13% share of Ovid’s soticlestat royalties and $20 million for a royalty below 1% on TZIELD net sales.
Outlook, risks, and contingencies
- The filing provides no company-level numerical FY2024 revenue or earnings guidance. Management describes continued royalty-right acquisitions and a lean operating structure as strategic priorities. Potential catalysts include regulatory decisions for ensifentrine (FDA target date June 26, 2024), Merck’s V116 vaccine (target date June 17, 2024), and partner filings for soticlestat; these outcomes are uncertain.
- Revenue is exposed to partner product sales, partner development and commercialization decisions, regulatory outcomes, and generic competition. The filing highlights concentration: three partners each accounted for at least 10% of 2023 revenue, with the largest two accounting for 33% and 20% (partner identities are not specified in that disclosure).
- Captisol depends primarily on one supplier, Hovione, and the company has $28.8 million of Captisol purchase obligations, including $8.6 million expected within one year. Other risks include investment-value volatility, acquisition integration and valuation assumptions, and potential product, patent, reimbursement, and regulatory setbacks.
- Ligand reported a material weakness in controls over business-combination valuations, specifically review of acquired-intangible cash-flow forecasts and the discount rate for a contract liability. Management and the auditor concluded internal control over financial reporting was ineffective at December 31, 2023; the auditor nevertheless issued an unqualified opinion on the financial statements. Remediation is ongoing and the weakness was not yet considered remediated.
- Elutia commercial-license rights were placed on non-accrual and had a $3.2 million credit-loss adjustment due to performance and nonpayment concerns. A further $0.9 million impairment was recorded for Selexis commercial-license rights. The filing reports no pending legal matter expected to have a material adverse effect, while noting litigation outcomes remain uncertain.
Investor verification priorities
- Reconcile the $52.2 million of net income with operating income and the $46.4 million investment gain; assess recurring earnings excluding investment gains and other unusual items.
- Review the durability of royalty growth and product concentration, including partner sales trends and potential generic-entry timing for Evomela and Kyprolis.
- Verify the assumptions, carrying values, and potential future cash flows for Primrose, Novan, Ovid, and TZIELD-related investments and acquired rights.
- Monitor remediation and testing of the business-combination internal-control material weakness.
- Track Captisol demand, supplier continuity, purchase commitments, and compliance with revolving-credit covenants.